174 related articles for article (PubMed ID: 36355258)
1. CRISPR/Cas9-mediated abrogation of CD95L/CD95 signaling-induced glioma cell growth and immunosuppression increases survival in murine glioma models.
Quijano-Rubio C; Silginer M; Weller M
J Neurooncol; 2022 Nov; 160(2):299-310. PubMed ID: 36355258
[TBL] [Abstract][Full Text] [Related]
2. CD95 gene deletion may reduce clonogenic growth and invasiveness of human glioblastoma cells in a CD95 ligand-independent manner.
Quijano-Rubio C; Silginer M; Weller M
Cell Death Discov; 2022 Jul; 8(1):341. PubMed ID: 35906203
[TBL] [Abstract][Full Text] [Related]
3. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro.
Merz C; Strecker A; Sykora J; Hill O; Fricke H; Angel P; Gieffers C; Peterziel H
Anticancer Drugs; 2015 Aug; 26(7):716-27. PubMed ID: 25850884
[TBL] [Abstract][Full Text] [Related]
4. CD95 ligand: lethal weapon against malignant glioma?
Weller M; Kleihues P; Dichgans J; Ohgaki H
Brain Pathol; 1998 Apr; 8(2):285-93. PubMed ID: 9546287
[TBL] [Abstract][Full Text] [Related]
5. p53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis.
Pohl U; Wagenknecht B; Naumann U; Weller M
Cell Physiol Biochem; 1999; 9(1):29-37. PubMed ID: 10352342
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma.
Blaes J; Thomé CM; Pfenning PN; Rübmann P; Sahm F; Wick A; Bunse T; Schmenger T; Sykora J; von Deimling A; Wiestler B; Merz C; Jugold M; Haberkorn U; Abdollahi A; Debus J; Gieffers C; Kunz C; Bendszus M; Kluge M; Platten M; Fricke H; Wick W; Lemke D
Mol Cancer Res; 2018 May; 16(5):767-776. PubMed ID: 29453321
[TBL] [Abstract][Full Text] [Related]
7. APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo.
Eisele G; Roth P; Hasenbach K; Aulwurm S; Wolpert F; Tabatabai G; Wick W; Weller M
Neuro Oncol; 2011 Feb; 13(2):155-64. PubMed ID: 21183510
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases.
Risso V; Lafont E; Le Gallo M
Cell Death Dis; 2022 Mar; 13(3):248. PubMed ID: 35301281
[TBL] [Abstract][Full Text] [Related]
9. Irradiation induced clonogenic cell death of human malignant glioma cells does not require CD95/CD95L interactions.
Streffer JR; Schuster M; Pohl U; Belka C; Dichgans J; Bamberg M; Weller M
Anticancer Res; 1999; 19(6B):5265-9. PubMed ID: 10697547
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha enhances CD95L-induced apoptosis of human malignant glioma cells.
Roth W; Wagenknecht B; Dichgans J; Weller M
J Neuroimmunol; 1998 Jul; 87(1-2):121-9. PubMed ID: 9670853
[TBL] [Abstract][Full Text] [Related]
11. Cytoplasmic overexpression of CD95L in esophageal adenocarcinoma cells overcomes resistance to CD95-mediated apoptosis.
Watson GA; Naran S; Zhang X; Stang MT; Queiroz de Oliveira PE; Hughes SJ
Neoplasia; 2011 Mar; 13(3):198-205. PubMed ID: 21390183
[TBL] [Abstract][Full Text] [Related]
12. Signaling active CD95 receptor molecules trigger co-translocation of inactive CD95 molecules into lipid rafts.
Lang I; Fick A; Schäfer V; Giner T; Siegmund D; Wajant H
J Biol Chem; 2012 Jul; 287(28):24026-42. PubMed ID: 22645131
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia sensitizes human malignant glioma cells towards CD95L-induced cell death.
Steinbach JP; Wolburg H; Klumpp A; Weller M
J Neurochem; 2005 Mar; 92(6):1340-9. PubMed ID: 15748153
[TBL] [Abstract][Full Text] [Related]
14. CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice.
Behrens CK; Igney FH; Arnold B; Möller P; Krammer PH
J Immunol; 2001 Mar; 166(5):3240-7. PubMed ID: 11207278
[TBL] [Abstract][Full Text] [Related]
15. The dual role of the CD95 and CD95L signaling pathway in glioblastoma.
Zhang Y; Jin T; Dou Z; Wei B; Zhang B; Sun C
Front Immunol; 2022; 13():1029737. PubMed ID: 36505426
[TBL] [Abstract][Full Text] [Related]
16. CD95 (Fas) and CD95L (FasL)-mediated non-canonical signaling pathways.
Haymour L; Jean M; Smulski C; Legembre P
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):189004. PubMed ID: 37865305
[TBL] [Abstract][Full Text] [Related]
17. CD95/Fas ligand induced toxicity.
Haluck-Kangas A; Peter ME
Biochem Soc Trans; 2023 Feb; 51(1):21-29. PubMed ID: 36629505
[TBL] [Abstract][Full Text] [Related]
18. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis.
Roth W; Isenmann S; Nakamura M; Platten M; Wick W; Kleihues P; Bähr M; Ohgaki H; Ashkenazi A; Weller M
Cancer Res; 2001 Mar; 61(6):2759-65. PubMed ID: 11289159
[TBL] [Abstract][Full Text] [Related]
19. Quantitation of CD95 and CD95L mRNA expression in chronic and acute HIV-1 infection by competitive RT-PCR.
Pinti M; Nasi M; Moretti L; Mussini C; Petrusca D; Esposito R; Cossarizza A
Ann N Y Acad Sci; 2000; 926():46-51. PubMed ID: 11193040
[TBL] [Abstract][Full Text] [Related]
20. CD95 signaling in cancer treatment.
De la Rosa AJ; Gomez MA; Morales S; Padillo FJ; Muntane J
Curr Pharm Des; 2014; 20(17):2809-18. PubMed ID: 23944368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
